celecoxib has been researched along with Periodontitis in 9 studies
Periodontitis: Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP)." | 9.13 | The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. ( Damoulis, PD; Hibberd, PL; Papas, AS; Singh, M; Stark, PC; Yen, CA, 2008) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 5.35 | The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008) |
| " In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP)." | 5.13 | The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. ( Damoulis, PD; Hibberd, PL; Papas, AS; Singh, M; Stark, PC; Yen, CA, 2008) |
| "The present study was planned to evaluate the individual and combined effects of selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, and omega-3 fatty acid on the gingival tissue levels of prostaglandin E2 (PGE2), prostaglandin F2alpha (PGF2alpha), leukotriene B4 (LTB4), and platelet activating factor (PAF) in endotoxin-induced periodontitis in rats." | 3.73 | Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. ( Atilla, G; Baylas, H; Berdeli, AH; Buduneli, E; Buduneli, N; Vardar, S, 2005) |
| "The aim of this study was to evaluate the effects of selective cyclooxygenase-2 inhibitor, celecoxib, and omega-3 fatty acid on serum levels of interleukin 1-beta (IL-1beta), osteocalcin (OC), and C-reactive protein (CRP) in experimental periodontitis." | 3.73 | Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Kinane, DF; Lappin, D; Vardar-Sengül, S, 2006) |
| "These data provide evidence that systemic therapy with celecoxib can modify the progression of experimentally induced periodontitis in rats." | 3.71 | Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. ( Holzhausen, M; Marcantonio Júnior, E; Nassar, PO; Rossa Júnior, C; Spolidório, DM; Spolidório, LC, 2002) |
| "Postoperative pain was accessed during the first 8 hours and on the following 3 days using the visual analog scale (VAS), the 101-point numerical rate scale (NRS-101), and the four-point verbal rating scale (VRS-4)." | 2.72 | The use of celecoxib and dexamethasone for the prevention and control of postoperative pain after periodontal surgery. ( André dos Santos, F; Bianchi, A; Cavassim, R; Pilatti, GL; Tozetto, CW, 2006) |
| "Alveolar bone loss was evaluated morphometrically under a stereomicroscope." | 1.35 | The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008) |
| "Arachidonic acid metabolites have been implicated in development of periodontal disease, especially those derived from the cyclo-oxygenase (COX) pathway." | 1.35 | Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats. ( Caliari, MV; Duarte, ID; Francischi, JN; Maltos, KL; Pacheco, CM; Queiroz-Junior, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, P | 2 |
| Farooq, U | 1 |
| Nainwal, LM | 1 |
| Alam, M | 1 |
| Poonkuzhi, NP | 1 |
| Kuruniyan, MS | 1 |
| Mirza, MA | 2 |
| Iqbal, Z | 2 |
| Vardar-Sengul, S | 2 |
| Buduneli, E | 3 |
| Turkoglu, O | 1 |
| Buduneli, N | 3 |
| Atilla, G | 3 |
| Wahlgren, J | 1 |
| Sorsa, T | 1 |
| Baylas, H | 3 |
| Queiroz-Junior, CM | 1 |
| Pacheco, CM | 1 |
| Maltos, KL | 1 |
| Caliari, MV | 1 |
| Duarte, ID | 1 |
| Francischi, JN | 1 |
| Holzhausen, M | 1 |
| Rossa Júnior, C | 1 |
| Marcantonio Júnior, E | 1 |
| Nassar, PO | 1 |
| Spolidório, DM | 1 |
| Spolidório, LC | 1 |
| Vardar, S | 1 |
| Berdeli, AH | 1 |
| Lappin, D | 1 |
| Kinane, DF | 1 |
| Pilatti, GL | 1 |
| André dos Santos, F | 1 |
| Bianchi, A | 1 |
| Cavassim, R | 1 |
| Tozetto, CW | 1 |
| Yen, CA | 1 |
| Damoulis, PD | 1 |
| Stark, PC | 1 |
| Hibberd, PL | 1 |
| Singh, M | 1 |
| Papas, AS | 1 |
2 trials available for celecoxib and Periodontitis
| Article | Year |
|---|---|
The use of celecoxib and dexamethasone for the prevention and control of postoperative pain after periodontal surgery.
Topics: Adult; Anti-Inflammatory Agents; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dexamet | 2006 |
The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Combin | 2008 |
7 other studies available for celecoxib and Periodontitis
| Article | Year |
|---|---|
Topics: Anti-Bacterial Agents; Celecoxib; Doxycycline; Humans; Hydroxyapatites; Matrix Metalloproteinase 13; | 2022 |
A 4-D approach for amelioration of periodontitis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Combined Modality Therapy | 2019 |
The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis.
Topics: Alveolar Bone Loss; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Co | 2008 |
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Topics: Alveolar Bone Loss; Animals; Arachidonic Acid; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, | 2009 |
Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.
Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2002 |
Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dinoprost; D | 2005 |
Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats.
Topics: Alveolar Bone Loss; Animals; C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Endotoxins; | 2006 |